Health

AstraZeneca Confirms Strong Vaccine Protection After US Rift

Published

3 years ago

March 25, 2021

AstraZeneca insists that its COVID-19 vaccine is strongly effective even after counting additional illnesses in its U.S. study, the latest in an extraordinary public dispute with American officials.

In a late-night news release Wednesday, the drugmaker said it had analyzed more data from that study and concluded the vaccine is 76% effective in preventing symptomatic COVID-19, instead of the 79% it had reported earlier in the week.

Just a day earlier, an independent panel that oversees the study had accused AstraZeneca of cherry-picking data to tout the protection offered by its vaccine.

The panel, in a harsh letter to the company and to U.S. health leaders, said the company had left out some COVID-19 cases that occurred in the study, a move that could erode trust in the science.

Some experts said the new data provided by AstraZeneca was “reassuring” and that the information was likely solid enough for U.S. regulators to authorize the vaccine.

“AstraZeneca may have just been too hasty in submitting the earlier, incomplete interim analysis rather than waiting to analyze and submit the full dataset,” said Julian Tang, a virologist at the University of Leicester who was not connected to the research.

He said the updated details didn’t look substantially different from what was published earlier this week.

Data disputes during ongoing studies typically remain confidential but in an unusual step, the National Institutes of Health publicly called on AstraZeneca to fix the discrepancy.

AstraZeneca had been counting on findings from a predominantly U.S. study of 32,000 people to help rebuild confidence in a vaccine that, despite being widely used in Britain, Europe and other countries, has had a troubled rollout.

Previous studies have turned up inconsistent data about its effectiveness, and then last week a scare about blood clots had some countries temporarily pausing inoculations.

Most have since restarted after the European Medicines Agency said the vaccine doesn’t increase the overall incidence of blood clots.

But it could not rule out a connection to some rare blood clots and issued new advice for monitoring those who get vaccinated.

Now the question is whether the company’s newest calculations can end the tension. Even before the latest spat, experts had expressed concern that missteps in the vaccine’s rollout could undermine confidence in the shot, which is crucial to global efforts to end the coronavirus pandemic since it is cheap, easy to store and a pillar of the COVAX initiative aimed at bringing vaccines to low- and middle-income countries.

Earlier Wednesday, Dr. Anthony Fauci, the top U.S. infectious disease expert, told reporters he hoped that when all the data was publicly vetted by federal regulators, it would dispel any hesitancy caused by the spat. He predicted it would “turn out to be a good vaccine.”

AstraZeneca’s newest calculations were based on 190 COVID-19 cases that occurred during the study, 49 more than it had included earlier in the week.

The vaccine appears especially protective against the worst outcomes, with no severe illnesses or hospitalizations among vaccinated study volunteers compared to eight severe cases among those given dummy shots, the company said. It didn’t provide a breakdown of the rest of the cases.

Some European authorities have questioned how protective the vaccine is in older adults. In the U.S. study, it was 85% effective in volunteers 65 and older, the company said. The study didn’t turn up safety concerns.

The updated information “confirms that our COVID-19 vaccine is highly effective in adults, including those aged 65 years and over,” AstraZeneca research chief Mene Pangalos said in a statement. He said the company looks forward to “the rollout of millions of doses across America.”

The study hasn’t ended, so additional COVID-19 cases can still accrue. AstraZeneca cautioned that 14 additional possible cases already are being examined and that could lead to further changes in the data.

The company intends to seek Food and Drug Administration clearance of the vaccine within a few weeks. The FDA will publicly debate all the evidence with its outside advisers before making a decision.

Stephen Evans, a vaccines expert at the London School of Hygiene and Tropical Medicine, said it was difficult to understand why the dispute between AstraZeneca and U.S. officials spilled into the public.

“Given the details given here, it seems an unnecessary action to have raised concerns in public,” he said. “Results fluctuate as data accumulate … what counts will be the FDA assessment and that will be done based on scrutiny of the full data and not press releases.”

He said any vaccine with an efficacy rate higher than 60% is useful.

He said it was unclear why there was “a breakdown in relations” between AstraZeneca and the independent U.S. data experts monitoring the trial and worried that could undermine confidence in the vaccine.

“This vaccine is so important for global health, and the disputes do not promote global health,” he said.

“At least in the short term, (this) will undermine confidence both in the U.S. and more importantly in the rest of the world.”

(AP)

Health

AUTISM: What You Need To Know

Published

2 weeks ago

April 6, 2024

Editor

By Silver Yeibake

Autism, commonly known as Autism Spectrum Disorder (ASD), is a neurodevelopmental disorder that affects communication, social interaction, and behavior. Autism is referred to as a spectrum condition since it can manifest in a variety of symptoms and abilities. While the actual cause of autism is unknown, evidence suggests that genetic and environmental factors interact to influence its development.

The risk factors include a sibling with autism, advanced age of parents, exposure to certain air pollutants and pesticides before birth, extreme prematurity, mothers with diabetes, immune system disorders or obesity, any difficulty with delivery leading to deprivation of oxygen to the baby’s brain, fever during pregnancy, lack of certain vitamins minerals during pregnancy, and certain genetic conditions, such as Down, fragile X, and Rett syndromes.

“Risk factors can not on their own cause a disease. However, they can increase the likelihood of that disease in a person.”

It is important to know that contrary to trending claims online, there is no scientific or medical evidence that vaccines or consumption of sugar are risk factors for autism.

Autism is defined by difficulties in social interaction and communication. Individuals with autism may struggle to grasp social cues, maintain eye contact, and engage in typical back-and-forth conversations. Some people may also engage in meaningless, repetitive actions, such as hand-flapping or rocking, and have strong interests in specific areas.

It is essential to remember that autism is a lifelong diagnosis, but with early intervention and adequate care, people with autism can live fulfilling lives.
Autism treatment frequently includes behavioral therapy, speech therapy, occupational therapy, and social skills training. Each individual with autism is unique, thus interventions should be tailored to meet their personal needs and strengths.

In spite of the difficulties that autism can cause, many people with autism possess unique talents and abilities. Some people may succeed in fields such as music, art, mathematics, or programming, thus it is important for society to acknowledge and honor the qualities and achievements of people with autism.

In summary, autism is a complicated and diverse disorder that affects individuals in various ways. By raising autism knowledge, understanding, and acceptance, we can build a more inclusive society in which people with autism can thrive and attain their full potential.

Dr. Yeibake, Weriwoyingipre Silver.
Senior Registrar,
Faculty Of Pediatrics,
WACP

Health

Don Confirms ‘Zobo’ As Antihypertensive Therapy

Published

1 month ago

March 10, 2024

Editor

The Deputy Vice Chancellor, University of Nigeria Enugu Campus, UNEC, Prof. Daniel Nwachukwu, after research findings and clinical trials in both animals and human, has confirmed that Hibiscus Sabdariffa, popularly called ‘zobo’ drinks, has all the curative potentials as an antihypertensive therapy.

Nwachukwu, who is a Professor of Cardiovascular Physiology in the university, stated that the antihypertensive effectiveness of the Hibiscus Sabdariffa (zobo) was comparable to those of known antihypertensive drugs that are popular in the retail pharmacies, adding that zobo’s availability, cheapness and absence of side effects make it attractive as an alternative therapeutic agent in mind to moderate hypertensive subjects.

He however cautioned that care should be applied to avoid abuse in the consumption of Hibiscus Sabdariffa (zobo), adding that the therapy could interfere with some anti-malaria drugs while its high dose was also reported to have toxic effects on the liver and kidney.

Nwachukwu’s discoveries were contained his 201st Inaugural Lecture of the University of Nigeria with the topic “The Marriage Between the Cardiovascular System and Hibiscus Sabariffa: Let no One Put Asunder,” delivered at the moot court hall, Law faculty of the University of Nigeria, Enugu campus.

The DVC warned that Hibiscus Sabariffa consumption is not recommended for persons with low blood pressure because of its well established hypotensive action, advising that during combined therapy with antihypertensive drugs, the blood pressure, BP, must be carefully monitored.

He recommended that industrialists and investors should support large scale production of Hibiscus Sabariffa beverage and its distribution to rural communities in Nigeria, particularly since the raw materials (Hibiscus Sabariffa calyx and water) are cheap and readily available.

According to Nwachukwu, “This lecture is intended to draw the public attention to our research efforts and unveiling the antihypertensive ability of Hibiscus Sabariffa which is called zobo in our common parlance. What we used for our studies was the same concentration as the locally produced zobo, and we found out that it exerted significant antihypertensive ability, in some cases even higher than the antihypertensive drugs and also did combination therapy with other antihypertensive drugs.

“What is significant is that this zobo is within us, it’s very cheap and it does not have any side effects compared to other antihypertensive agents. The raw material is just to buy zobo, prepare it under hygienic conditions, boil water and put it, sieve it and drink. It may have a sour taste but we do not encourage people to add things like pineapple or sugar in order to make it sweet, because once you do that, you are diluting or reducing its antihypertensive effectiveness.

“We have demonstrated it, both in animal studies and in humans. We are the first to do clinical trials, using mild to moderate antihypertensive Nigerians and we found it very useful. Some of the results show that one can actually use it and we equally saw that you can use it to prevent even diabetes from occurring because it reduces the rise in glucose level.”

Vice Chancellor of the University, Professor Charles Igwe while summarizing the lecture said that the lecture was in three dimensions; one on health grounds, another in academics and the third an economic value.

“Its economic in the sense that we can also begin to use what God has given us to make money. Maybe because God gave us everything in abundance in this country, we don’t recognize the simplest things God gave us in our environment. Therefore, what we are saying is that we should begin to, at all these pure water productions and incorporate zobo production so as to make money out of it.

“The university has made its contribution through our laboratories and it’s now left for the business community and the industries to come and buy into it and start widening it and make it very economic,” Igwe suggested.
Vanguard

Health

Glaucoma: What You Need To Know

Published

1 month ago

March 8, 2024

Editor

By Silver Yeibake

Hi, did you know that Tuesday 12th March, 2024 is world Glaucoma day?Kindly avail yourself of this opportunity to learn about this important health issue as presented below:

Glaucoma is a dangerous eye disorder that damages the optic nerve, causing visual impairment or permanent blindness if not treated.
The optic nerve transmits visual information from the eye to the brain. Damage to this nerve might cause gradual visual loss that is not immediately obvious.

Worldwide, this disease affects 67 million people and contributes 6.7 million of blindness in this population. Glaucoma is the leading cause of blindness in the world.
The total number of cases is expected to increase to 111 million by 2040. Males are slightly more affected than females.

One of the basic causes of glaucoma is an increase in intraocular pressure (pressure within the eyeball), which can eventually damage the optic nerve (the nerve that makes seeing possible). This increase in pressure could be caused by an accumulation of aqueous humor, the fluid that nourishes the eye.

FROM THE AUTHOR: Food Poisoning: What You Need To Know

There are several forms of glaucoma, including open-angle glaucoma, angle-closure glaucoma, normal-tension glaucoma, and secondary glaucoma, each with unique characteristics and treatment choices.

Some of the risk factors for glaucoma include sustained elevation of intraocular pressure, family history of glaucoma, race (African, Asian), short-sightedness, long-sightedness, age over 50, previous eye injury or surgery, hypertension, diabetes mellitus, migraines, and prolonged steroid therapy.

Glaucoma symptoms may not appear until the problem has advanced sufficiently, therefore regular eye checks are essential for early detection. Blurred vision, eye pain, nausea, and light halos are some of the most frequent glaucoma symptoms. However, these symptoms might be mild or readily misinterpreted as other eye problems, emphasizing the significance of regular eye examinations.

Glaucoma treatment tries to reduce intraocular pressure and protect the optic nerve from further damage. This can be accomplished using a variety of approaches, including prescription eye drops, oral medicines, laser therapy, and surgical procedures. Treatment options are determined on the kind and severity of glaucoma, as well as personal characteristics such as overall health and medical history.

To summarize, glaucoma is a serious eye disorder that requires timely diagnosis and treatment to prevent irreversible vision loss. Regular eye examinations, early detection, and commitment to treatment plans are critical for protecting vision and eye health in glaucoma patients.
Thank you.

Dr. Yeibake, Weriwoyingipre Silver, a
Senior Registrar, Faculty Of Pediatrics, West Africa College of Physician (WACP), writes from Yenagoa, Bayelsa State.